<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02978755</url>
  </required_header>
  <id_info>
    <org_study_id>C101</org_study_id>
    <nct_id>NCT02978755</nct_id>
  </id_info>
  <brief_title>First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers</brief_title>
  <official_title>Open, Non Controlled, Multicenter, Firs-in-human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GamaMabs Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GamaMabs Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in human study, assessing the safety profile, the pharmacokinetics and preliminary
      antitumor activity of GM102, a new compound (a monoclonal antibody), in patients with
      previously treated gynecological cancers bearing the AMHRII (anti-mullerian Hormone Receptor
      II) receptor. The primary objective of the study is to determine the GM102 recommended dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMHRII is reexpressed in a subset of gynecological cancers. GM102 is a humanized low fucose
      monoclonal antibody with a high affinity to AMHRII receptor. GM102 acts through enhanced
      capability to engage immune effector cells (macrophages, natural killer (NK) cells) to
      trigger ADCC (antibody dependent cellular cytotoxicity) and phagocytosis of tumor cells.

      Patients with gynecological tumors expressing AMHRII receptor on the tumor cells in archived
      tissue as determined prior to study entry will be eligible for C101 study.

      C101 consists of a phase I part (dose and schedule escalation) and a phase Ib part
      (expansion).

      The phase I part is designed to determine the recommended phase 2 dose (RP2D) using the
      classical 3+3 dose-finding design. In six successive escalating dose cohorts, patients will
      receive GM102 infusions every 2 weeks until progression or toxicity. In 4 additional cohorts,
      patients will receive GM102 infusions weekly until progression or toxicity and GM102
      infusions combined with chemotherapy until progression or toxicity.

      A Trial Steering Committee (TSC) will analyze and qualify the toxicities and will provide
      recommendations according to the dose administration rules defined in the protocol.

      At the end of the phase I part, the RP2D will be determined, taking into account dose
      limiting toxicities (DLTs), overall toxicity, pharmacokinetics and pharmacodynamics effects
      of GM102.

      The Phase Ib part of the study will confirm the tolerance of the selected dose (RP2D) and
      will assess antitumoral activity of GM102 in three parallel cohorts of patients with Sex
      Cord-Stromal tumors, and AMHRII positive ovarian and cervix cancers. Patients will be treated
      until progression or toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>phase 1 escalation GM102 single agent
phase 1 escalation GM102 combined with paclitaxel and carboplatin
phase 1b: 3 parallel expansion cohorts at the recommended dose of GM102 single agent</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I part: incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Four weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib part: incidence of Serious Adverse Events (SAEs) and Treatment-Emergent Adverse Events (TEAEs) at Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration [Cmax]</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>Cycle 1 Day 1 pre-dose, Cycle 1 Day 1 End Of Infusion (EOI), Cycle 1 Day 1 EOI + 3 hours, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 1 Day 8, Cycle 1 Day 15 pre-dose, Cycle 1 Day 15 EOI, Cycle 2 Day 1 pre-dose, Cycle 2 Day 1 EOI, Cycle 2 Day 15 pre-dose, Cycle 2 Day 15 EOI, Cycle 3 Day 1 pre-dose, Cycle 3 Day 1 EOI, Cycle 3 Day 15 pre-dose, Cycle 3 Day 15 EOI, Cycle 4 Day 1 pre-dose, Cycle 4 Day 1 EOI, Cycle 4 Day 15 pre-dose, Cycle 4 Day 15 EOI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>Cycle 1 Day 1 pre-dose, Cycle 1 Day 1 End Of Infusion (EOI), Cycle 1 Day 1 EOI + 3 hours, Cycle 1 Day 2, Cycle 1 Day 3, Cycle 1 Day 8, Cycle 1 Day 15 pre-dose, Cycle 1 Day 15 EOI, Cycle 2 Day 1 pre-dose, Cycle 2 Day 1 EOI, Cycle 2 Day 15 pre-dose, Cycle 2 Day 15 EOI, Cycle 3 Day 1 pre-dose, Cycle 3 Day 1 EOI, Cycle 3 Day 15 pre-dose, Cycle 3 Day 15 EOI, Cycle 4 Day 1 pre-dose, Cycle 4 Day 1 EOI, Cycle 4 Day 15 pre-dose, Cycle 4 Day 15 EOI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate defined as percentage of patients achieving Complete Response (CR), Partial Response (PR) or Stable Disease (SD) superior to 3 months</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Neoplasm, Gynecologic</condition>
  <arm_group>
    <arm_group_label>GM102 escalating doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 successive cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GM102 escalating doses + carboplatin+paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 successive cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GM102 recommended dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 parallel cohorts in sex cord stromal, epithelial ovarian and cervix cancers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM102</intervention_name>
    <description>GM102 escalating doses (phase1)</description>
    <arm_group_label>GM102 escalating doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + carboplatin</intervention_name>
    <description>GM102 escalating doses combined with paclitaxel and carboplatin</description>
    <arm_group_label>GM102 escalating doses + carboplatin+paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM102</intervention_name>
    <description>GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)</description>
    <arm_group_label>GM102 recommended dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Locally advanced, or metastatic recurrent gynecological cancer, for whom no standard
             alternative therapy is available, having received at least one line of therapy and
             expressing AMHRII on tumor cells.

          -  If possible at least one lesion should be identified for 2 biopsies: a baseline biopsy
             and an under-treatment biopsy for AMHRII expression and GM102 pharmacodynamics
             evaluation.

          -  Available tumor block or at least 10 slides from formalin-fixed paraffin-embedded
             (FFPE) archival tissue.

          -  At least one measurable lesion by RECIST (Response Evaluation Criteria in Solid
             Tumors) on screening CT-scan.

          -  Written Informed Consent forms.

          -  Willing and able to comply with the trial requirements.

          -  Covered by healthcare insurance in accordance with local requirements.

        For phase 1b, only patients with either Sex cord stromal tumors or epithelial ovarian
        cancer or cervix cancer will be eligible

        Exclusion Criteria:

          -  Age &lt; 18 years old.

          -  Eastern Cooperative Oncology Group (ECOG) performance status &gt; 1

          -  Life expectancy &lt; 12 weeks.

          -  Known or symptomatic brain metastasis (other than totally resected or previously
             irradiated and non-progressive/relapsing) or lepto-meningeal carcinomatosis.

          -  Concurrent treatment with any other anticancer therapy.

          -  Concurrent chronic corticosteroid treatment.

          -  Known severe anaphylactic or other hypersensitivity reactions secondary to a prior
             exposure to human antibodies or to any protein product.

          -  Washout period before treatment initiation: &lt; 3 weeks or 5 times the half-life,
             whichever is shorter, for prior antitumor therapy (small molecules and/or
             antibody-drug conjugates, radiotherapy) or 6 weeks for monoclonal antibodies.

          -  Any active concomitant malignancy.

          -  Serious concomitant illness e.g. active infection requiring systemic antibiotic,
             antifungal or antiviral drug, or physical examination or laboratory abnormalities,
             that, in the opinion of the Investigator, would compromise protocol objectives.

          -  Poor bone marrow reserve as defined by neutrophils &lt; 1.0 x 10E9/L or haemoglobin &lt; 9.0
             g/dL or platelet count &lt; 100 x 10E9/L.

          -  Poor organ function as defined by any one of the following: left ventricular ejection
             fraction â‰¤ 40%, serum creatinine &gt; 1.5 x upper limit of normal (ULN), total bilirubin
             &gt; 1.5 x ULN, AST and ALT&gt; 2.5 x ULN in the absence of liver metastasis or &gt; 5 x ULN in
             case of documented liver metastasis.

          -  Non-resolution of any prior treatment related toxicity to &lt; Grade 2, except for
             alopecia according to National Cancer Institute-Common Terminology Criteria for
             Adverse Events (NCI-CTCAE) v4.03.

          -  Pregnancy or breastfeeding.

          -  Patient with reproductive potential who do not agree to use an accepted effective
             method of contraception - investigator's judgment - during the study period and for at
             least 4 months following completion of study treatment.

          -  Patient participating in another clinical trial investigating a treatment during the
             study and within 30 days prior to first study treatment administration.

          -  Patient deprived of her liberty by a judicial or administrative decision, patient
             admitted to a hospital, social institution or who is under a measure of legal
             protection, patient hospitalized without consent or who is in an emergency situation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Isabelle Tabah-Fisch</last_name>
    <phone>+33 1 73 02 51 88</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Berengere Jean</last_name>
    <phone>+33 5 31 61 60 71</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Billiet</last_name>
    </contact>
    <investigator>
      <last_name>Amad Awada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nabila Adrar</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Le Tourneau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire Cancer Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessy Saffore</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Delord</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Houda Pousse-Bencheikh</last_name>
    </contact>
    <investigator>
      <last_name>Alexandra Leary</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2016</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

